Aboubakar Nana, Frank
Mayo Clinic
Université Catholique de Louvain (UCLouvain), Brussels, Belgium.
Citations 2
Clinical outcomes and safety of immune checkpoint inhibitors in patients with solid tumors and paraneoplastic syndromes
Zarif, Talal El , Khalid, Ahmed Bilal, Rahme, Serena, Zhong, Caiwei , Salame, Marita , Freeman, Dory , El‐Am, Edward , Ravishankar, Arjun , Ahmad, Bachar , Nana, Frank Aboubakar , Kaldas, David , Naqash, Abdul Rafeh , LeBoeuf, Nicole R. , Malgeri, Andrea , Gupta, Shruti , Al‐Hader, Ahmad, Sparks, Jeffrey A. , Linnoila, Jenny, McKay, Rana R. , Dilling, Thomas J. , Adib, Elio , Najem, Elie, Kim, So Yeon , Sonpavde, Guru , El Zarif, Talal , Gupta, Shruti , Marron, Thomas , Choueiri, Toni K , Adib, Elio , Kim, So Yeon , Sonpavde, Guru , Sparks, Jeffrey A , Aboubakar Nana, Frank , Naqash, Abdul Rafeh , Nassar, Amin H. , Kwak, Lucia , Farhat, Elias Bou , Sharon, Elad , Cortellini, Alessio , Hamnvik, Ole‐Petter R. , Mouhieddine, Tarek H. , Parikh, Kaushal , Choueiri, Toni K.
Journal for ImmunoTherapy of Cancer | March 5, 2024 | Volume: 12 | Issue: 3 | Pages: e008724
Background Patients with paraneoplastic syndromes (PNS) are excluded from clinical trials involving immune checkpoint inhibitors (ICIs) due to safety concerns. Moreover, real-world data on efficacy and safety is scarce. Methods In this retrospective study, data were collected on patients with PNS and solid tumors receiving ICI between 2015 and 2022 at nine institutions. Patients were classified into: Cohort 1 (pre-existing PNS before ICI initiation), cohort 2 (PNS during ICI treatment), and cohort 3 (PNS after ICI discontinuation). Patients with metastatic non-small cell lung cancer (NSCLC) (mNSCLC) from cohort 1 were matched to patients who were PNS-free at each institution up to a 1:3 ratio for age, sex, type of ICI, use of concurrent chemotherapy, and number of lines of systemic therapy prior to ICI initiation. Kaplan-Meier method was used to assess overall survival (OS) and time-to-next treatment (TTNT). Results Among 109 patients with PNS treated with ICIs, median age at ICI initiation was 67 years (IQR: 58–74). The most represented cancer type was NSCLC (n=39, 36%). In cohort 1 (n=55), PNS exacerbations occurred in 16 (29%) patients with median time to exacerbation after ICI of 1.1 months (IQR: 0.7–3.3). Exacerbation or de novo PNS prompted temporary/permanent interruption of ICIs in 14 (13%) patients. For cohort 2 (n=16), median time between ICI initiation and de novo PNS was 1.2 months (IQR: 0.4–3.5). Treatment-related adverse events (trAEs) occurred in 43 (39%) patients. Grade ≥3 trAEs occurred in 18 (17%) patients. PNS-directed immunosuppressive therapy was required in 55 (50%) patients. We matched 18 patients with mNSCLC and PNS (cohort 1) to 40 without PNS, treated with ICIs. There was no significant difference in OS or TTNT between patients with mNSCLC with and without PNS, although a trend was seen towards worse outcomes in patients with PNS. TrAEs occurred in 6/18 (33%) and 14/40 (35%), respectively. Grade ≥3 trAEs occurred in 4 (22%) patients with PNS and 7 (18%) patients without PNS. Conclusions Exacerbations of pre-existing PNS occurred in 29% of patients treated with ICIs and both exacerbations and de novo PNS occur early in the ICI course. TrAE from ICIs were similar between patients with and without PNS. Our data suggest that pre-existing PNS should not preclude consideration of ICI therapy although patients may not derive the same clinical benefit compared with patients without PNS.
Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium
Zarif, Talal El , Nassar, Amin H. , Adib, Elio , Fitzgerald, Bailey G. , Huang, Jiaming , Mouhieddine, Tarek H. , Rubinstein, P , Nonato, Taylor K., McKay, Rana R. , Li, Mingjia , Baiocchi, Robert A. , Lorentsen, Michael , Dittus, Christopher , Dizman, Nazlı , Falohun, Adewunmi, Abdel‐Wahab, Noha , Diab, Adi , Bankapur, Anand, Reed, Alexandra, Kim, Chul , Arora, Aakriti, El‐Am, Edward , Abdallah, Wassim , Al‐Hader, Ahmad, Ghazal, Batool Abu, Drolen, Claire , Drakaki, Alexandra , Baena, Javier , Nebhan, Caroline A. , Haykal, Tarek , Morse, Michael A. , Cortellini, Alessio , Pinato, David J. , Pria, Alessia Dalla , Bakalov, Veli , Bahary, Nathan , Rajkumar, Aarthi , Mangla, Ankit , Singh, Parminder , Nana, Frank Aboubakar , Lopetegui‐Lia, Nerea , Dobbs, Ryan W. , Funchain, Pauline , Long, Georgina V. , Genova, Carlo , Barletta, Giulia, Idossa, Damé , Lamberti, Giuseppe , Freeman, Dory , Chiao, Elizabeth Y. , Johnson, Douglas B. , Ramaswami, Ramya , Bower, Mark , Emu, Brinda , Baden, Lindsey R. , Sonpavde, Guru , Naqash, Abdul Rafeh , El Zarif, Talal , Rubinstein, Paul G , Mittra, Arjun , Owen, Dwight H , Lorentsen, Michael , Dittus, Christopher , Dizman, Nazli , Abdel-Wahab, Noha , Diab, Adi , Kim, Chul , Shah, Neil J , Kozaily, Elie , Abdallah, Wassim , Saeed, Anwaar , Drolen, Claire , Lechner, Melissa G , Drakaki, Alexandra , Nebhan, Caroline A , Haykal, Tarek , Cortellini, Alessio , Pinato, David J , Dalla Pria, Alessia , Hall, Evan , Bahary, Nathan , Mangla, Ankit , Shah, Vishal , Aboubakar Nana, Frank , Lopetegui-Lia, Nerea , Dima, Danai , Dobbs, Ryan W , Funchain, Pauline , Woodford, Rachel , Long, Georgina V , Menzies, Alexander M , Genova, Carlo , Puri, Sonam , Florou, Vaia , Lamberti, Giuseppe , Addeo, Alfredo , Bersanelli, Melissa , Xie, Wanling , Reid, Erin G , Chiao, Elizabeth Y , Sharon, Elad , Johnson, Douglas B , Ramaswami, Ramya , Bower, Mark , Choueiri, Toni K , Lurain, Kathryn , Sonpavde, Guru , Naqash, Abdul Rafeh , Nassar, Amin H. , Singh, Parminder , Saeed, Anwaar , Shah, Vishal , Dima, Danai , Saleem, Rabia, Saponara, Maristella , Queirolo, Paola , Addeo, Alfredo , Xie, Wanling , Sharon, Elad , Marron, Thomas , Choueiri, Toni K. , Espinar, Javier Baena
Journal of Clinical Oncology | May 16, 2023 | Volume: 41 | Issue: 21 | Pages: 3712-3723
PURPOSE Compared with people living without HIV (PWOH), people living with HIV (PWH) and cancer have traditionally been excluded from immune checkpoint inhibitor (ICI) trials. Furthermore, there is a paucity of real-world data on the use of ICIs in PWH and cancer. METHODS This retrospective study included PWH treated with anti–PD-1- or anti–PD-L1-based therapies for advanced cancers. Kaplan-Meier method was used to estimate overall survival (OS) and progression-free survival (PFS). Objective response rates (ORRs) were measured per RECIST 1.1 or other tumor-specific criteria, whenever feasible. Restricted mean survival time (RMST) was used to compare OS and PFS between matched PWH and PWOH with metastatic NSCLC (mNSCLC). RESULTS Among 390 PWH, median age was 58 years, 85% (n = 331) were males, 36% (n = 138) were Black; 70% (n = 274) received anti–PD-1/anti–PD-L1 monotherapy. Most common cancers were NSCLC (28%, n = 111), hepatocellular carcinoma ([HCC]; 11%, n = 44), and head and neck squamous cell carcinoma (HNSCC; 10%, n = 39). Seventy percent (152/216) had CD4+ T cell counts ≥200 cells/µL, and 94% (179/190) had HIV viral load <400 copies/mL. Twenty percent (79/390) had any grade immune-related adverse events (irAEs) and 7.7% (30/390) had grade ≥3 irAEs. ORRs were 69% (nonmelanoma skin cancer), 31% (NSCLC), 16% (HCC), and 11% (HNSCC). In the matched mNSCLC cohort (61 PWH v 110 PWOH), 20% (12/61) PWH and 22% (24/110) PWOH had irAEs. Adjusted 42-month RMST difference was –0.06 months (95% CI, –5.49 to 5.37; P = .98) for PFS and 2.23 months (95% CI, –4.02 to 8.48; P = .48) for OS. CONCLUSION Among PWH, ICIs demonstrated differential activity across cancer types with no excess toxicity. Safety and activity of ICIs were similar between matched cohorts of PWH and PWOH with mNSCLC.